JTCS Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Antunes, M. J.
Right arrow Articles by Fernandes, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antunes, M. J.
Right arrow Articles by Fernandes, L. E.

The Journal of Thoracic and Cardiovascular Surgery, Vol 95, 980-993, Copyright © 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Medtronic Hall valve replacement in a third-world population group. A review of the performance of 1000 prostheses

MJ Antunes, A Wessels, RG Sadowski, JG Schutz, KM Vanderdonck, JM Oliveira and LE Fernandes
Division of Cardiothoracic Surgery, Johannesburg Group of Teaching Hospitals, Republic of South Africa.

Between May 1980 and December 1984, 1000 Medtronic Hall prostheses (538 mitral and 462 aortic) were implanted in 852 patients (mean age 30 +/- 15 years) of a third-world type of population group. The most common valve lesions were aortic and mitral regurgitation, and 32% of the patients were in New York Heart Association class IV or greater. Double valve (aortic and mitral) operations were performed in 209 patients. The 782 operative survivors were followed up for 2 to 6.5 years (mean 3.5 years) for a cumulative 2676 patient-years. Valve performance was analyzed in each position separately for valve-related complications. Results for the whole group for the following events are expressed in both linearized (percent/patient-year) and actuarial (percent +/- standard error of the mean freedom at 5 years) terms, respectively: valve-related mortality, 2.9 and 92 +/- 2; reoperation, 1.9 and 90 +/- 2; systemic thromboembolism, 3.3 and 85 +/- 2; thrombotic obstruction, 1.2 and 95 +/- 1; prosthetic valve endocarditis, 0.7 and 97 +/- 1; anticoagulant-related hemorrhage, 0.7 and 98 +/- 1; and periprosthetic leak, 0.7 and 97 +/- 1. Corresponding composite figures for valve failure were 4.3 and 85 +/- 2, and for all valve-related morbidity and mortality were 6.7 and 75 +/- 3. Thrombotic obstruction (fatal in 71% of the cases), anticoagulant-related hemorrhage (61% fatal), and prosthetic endocarditis (44% fatal) were the most lethal complications. Although the differences did not reach statistical significance, aortic prostheses appeared to have a higher incidence of complications than the mitral prostheses. When analyzed against the background of an essentially noncompliant population group, the Medtronic Hall prosthesis proved to be reliable and remarkably free from structural failure. The high incidence of thromboembolism and thrombotic obstruction still mandates anticoagulation.


This article has been cited by other articles:


Home page
Card Surg AdultHome page
T. Gudbjartsson, T. Absi, and S. Aranki
Mitral Valve Replacement
Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068.
[Full Text]


Home page
HeartHome page
V. T Nkomo
Epidemiology and prevention of valvular heart diseases and infective endocarditis in Africa
Heart, December 1, 2007; 93(12): 1510 - 1519.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
T. Gudbjartsson, S. Aranki, and L. H. Cohn
Mechanical/Bioprosthetic Mitral Valve Replacement
Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
A. C. Fiore, H. B. Barner, M. T. Swartz, L. R. McBride, A. J. Labovitz, K. J. Vaca, J. St. Vrain, G. L. Grunkemeier, and G. C. Kaiser
Mitral valve replacement: randomized trial of St. Jude and Medtronic Hall prostheses
Ann. Thorac. Surg., September 1, 1998; 66(3): 707 - 713.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. E.E. Kuntze, E. H. Blackstone, and T. Ebels
Thromboembolism and mechanical heart valves: a randomized study revisited
Ann. Thorac. Surg., July 1, 1998; 66(1): 101 - 107.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. E. David, V. L. Gott, L. A. Harker, G. E. Miller Jr, D. C. Naftel, A. G. G. Turpie, and C. W. Akins
Mechanical Valves
Ann. Thorac. Surg., November 1, 1996; 62(5): 1567 - 1570.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
C. W. Akins
Results With Mechanical Cardiac Valvular Prostheses
Ann. Thorac. Surg., December 1, 1995; 60(6): 1836 - 1844.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. G. Masters, A. L. Pipe, V. M. Walley, and W. J. Keon
Comparative results with the St. Jude Medical and Medtronic Hall mechanical valves
J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 663 - 671.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Ibrahim, H. O'Kane, J. Cleland, D. Gladstone, M. Sarsam, and C. Patterson
The St. Jude Medical prosthesisA thirteen-year experience
J. Thorac. Cardiovasc. Surg., August 1, 1994; 108(2): 221 - 230.
[Abstract] [Full Text]


Home page
Eur. J. Cardiothorac. Surg.Home page
C.W. Akins
Review of the global experience with the Medtronic-Hall valve
Eur. J. Cardiothorac. Surg., January 1, 1992; 6(suppl_1): S68 - S74.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1988 by The American Association for Thoracic Surgery.